HI-PRIX Health Innovation Next Generation Payment & Pricing Models
- Coordinator
- Universita Commerciale Luigi Bocconi, Italy
- Runs
- 1 January 2023 to 31 December 2025
- Status
- Running
- EU funding
- €4.0m
- Total cost
- €4.0m
- Partners
- 18 organisations in 10 countries
- Type
- Research and Innovation Action
- Grant agreement
- 101095593
What the project is doing
In the project's own words, from its summary on CORDIS.
The variety of innovative technologies with the potential to revolutionize the delivery of health care means that the policy toolbox will need several pricing and payment models, adapted in their design and implementation according to the specific situation. Although there are examples of novel pricing and payment models, the lack of appropriate data infrastructure, legal barriers and unwillingness to adapt current systems often prevent their use.
Therefore, the overall objectives of the Health Innovation Next Generation Pricing Models (HI – PRIX) project are: i) to map and formulate new pricing and payment schemes that can be used across technology classes, therapeutic areas, setting and healthcare systems/geographies together with a related set of principles that may guide successful adjustment and flexible implementation to the context of use; ii) to investigate the impact on competitiveness, innovation, equity and affordability of a pipeline of contracting modalities for health innovations; iii) to address the challenges and concerns of payers, manufacturers, healthcare professionals, and patients about different models of pricing by sustaining an effective dialogue across stakeholders’ groups about the trade-offs between affordability, innovation and patient access.
Coordinated by Bocconi University, the HI-PRIX Consortium involves 18 partners from 10 European countries, including academic institutions, public authorities, healthcare providers, and independent research organizations. Through theoretical models, quantitative simulation, qualitative research work and case-studies, this three-year project structured around 10 WPs, will generate new evidence on the role of public sector in R&D and indirect medical and environmental costs in pricing and reimbursement determinations, on the pricing dynamics over pharmaceutical products’ lifecycle, on the impact of policies and incentives on the competitiveness, innovativeness and equity in the healthcare system.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Universita Commerciale Luigi Bocconi | Milano | Italy | Coordinator |
| Hta Austria - Austrian Institute for Health Technology Assessment GmbH | Wien | Austria | Participant |
| Universite Libre De Bruxelles | Bruxelles | Belgium | Participant |
| University of Hamburg | Hamburg | Germany | Participant |
| Escuela Andaluza De Salud Publica SA | Granada | Spain | Participant |
| Fundacio De Recerca Clinic Barcelona-Institut D Investigacions Biomediques August Pi I Sunyer | Barcelona | Spain | Participant |
| Fundacion Publica Andaluza Progreso Y Salud M.p. | Sevilla | Spain | Participant |
| Hospital Clinic De Barcelona | Barcelona | Spain | Third party |
| Servei Catala De La Salut | Barcelona | Spain | Associatedpartner |
| Ecole D'economie De Paris | Paris | France | Participant |
| Agenzia Italiana Del Farmaco | Roma | Italy | Associatedpartner |
| Vilniaus Universitetas | Vilnius | Lithuania | Participant |
| Erasmus Universiteit Rotterdam | Rotterdam | Netherlands | Participant |
| Infarmed - Autoridade Nacional Do Medicamento E Produtos Da Saude Ip | Lisboa | Portugal | Associatedpartner |
| Universidade Nova De Lisboa | Lisboa | Portugal | Participant |
| Imperial College of Science Technology and Medicine | London | United Kingdom | Associatedpartner |
| London School of Economics and Political Science | London | United Kingdom | Associatedpartner |
| The Office of Health Economics | London | United Kingdom | Associatedpartner |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI